Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
8(73%)
Results Posted
200%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
6
55%
Ph phase_2
4
36%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

8

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(1)
Terminated(2)

Detailed Status

Recruiting6
Active, not recruiting2
Completed1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
8
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 24 (40.0%)

Trials by Status

completed19%
withdrawn19%
terminated19%
recruiting655%
active_not_recruiting218%

Recent Activity

8 active trials
Showing 5 of 11
active_not_recruiting

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

NCT04286386
recruitingphase_1

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

NCT04540107
recruitingphase_1

Hyperpolarized Imaging in Diagnosing Participants With Glioma

NCT03739411
active_not_recruitingphase_2

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

NCT04258462
recruitingphase_2

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

NCT03933670
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04286386

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

Active Not Recruiting
NCT04540107Phase 1

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting
NCT03739411Phase 1

Hyperpolarized Imaging in Diagnosing Participants With Glioma

Recruiting
NCT04258462Phase 2

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Active Not Recruiting
NCT03933670Phase 2

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Recruiting
NCT03830151Phase 1

Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

Recruiting
NCT04589624Phase 1

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Recruiting
NCT06014905Phase 1

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Recruiting
NCT03581500Phase 2

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Withdrawn
NCT03565367Phase 1

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Completed
NCT04565327Phase 2

Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

Terminated

All 11 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
11